Annualized height velocity (mean + s.d.) in 53 subjects after 26 weeks of TransCon GH vs daily GH (Genotropin) treatment. Reproduced under the terms of the original CCBY licence, from Chatelain P, Malievskiy O, Radziuk K, Senatorova G, Abdou MO, Vlachopapadopoulou E, Skorodok Y, Peterkova V, Leff JA, Beckert M, et al. A randomized phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency, Journal of Clinical Endocrinology and Metabolism, 2017, volume 102, pages 1673–1682, (doi:10.1210/jc.2016-3776).